<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Mid-America Apartment Communities Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/mid-america-apartment-communities-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(MAA) MAA Acquires Virginia Property</title>
		<link>http://www.stockbloghub.com/2012/04/05/maa-maa-acquires-virginia-property/97732</link>
		<comments>http://www.stockbloghub.com/2012/04/05/maa-maa-acquires-virginia-property/97732#comments</comments>
		<pubDate>Thu, 05 Apr 2012 17:51:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[REIT - Residential]]></category>
		<category><![CDATA[3M Company]]></category>
		<category><![CDATA[AT&T Inc.]]></category>
		<category><![CDATA[BA]]></category>
		<category><![CDATA[Boeing Company]]></category>
		<category><![CDATA[FDX]]></category>
		<category><![CDATA[FedEx Corporation]]></category>
		<category><![CDATA[LMT]]></category>
		<category><![CDATA[Lockheed Martin Corporation]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[MMM]]></category>
		<category><![CDATA[T]]></category>
		<category><![CDATA[UDR]]></category>
		<category><![CDATA[UDR Inc.]]></category>
		<category><![CDATA[Xerox Corporation]]></category>
		<category><![CDATA[XRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97732</guid>
		<description><![CDATA[MAA (MAA), an apartment-only real estate investment trust (REIT), has recently completed the acquisition of Adalay Bay – a 240-unit upscale apartment community in Chesapeake, Virginia &#8212; for an undisclosed price. The transaction was funded with the proceeds from a secondary offering of approximately 1.96 million shares completed earlier in the year. Developed in 2002, Adalay Bay is strategically located in the Hampton Roads area of Chesapeake that houses the commercial Port of Hampton Roads, which is serviced by about 90% of the world&#8217;s shipping lines. The region is also famous for the presence of several Fortune 500 companies, including 3M (MMM), AT&#38;T (T), Boeing (BA), Federal Express (FDX), Xerox (XRX) and Lockheed Martin (LMT). Besides the booming technology industry, Hampton Roads also boasts a strong tourism industry with several ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/05/maa-maa-acquires-virginia-property/97732/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRTX) Vertex Pharmaceuticals Riding High on Incivek Sales</title>
		<link>http://www.stockbloghub.com/2011/11/02/vrtx-vertex-pharmaceuticals-riding-high-on-incivek-sales/86343</link>
		<comments>http://www.stockbloghub.com/2011/11/02/vrtx-vertex-pharmaceuticals-riding-high-on-incivek-sales/86343#comments</comments>
		<pubDate>Wed, 02 Nov 2011 17:08:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CF]]></category>
		<category><![CDATA[CF Industries Holdings Inc.]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86343</guid>
		<description><![CDATA[Vertex Pharmaceuticals Inc. (VRTX) posted robust third quarter 2011 earnings (including stock-based compensation expense) of 56 cents per share, substantially above the Zacks Consensus Estimate of 19 cents and the year-ago loss of 99 cents. Increased revenues from the sale of hepatitis C virus (HCV) treatment, Incivek (telaprevir) helped record positive earnings. Revenues Riding on the strong sales of Incivek, which was launched in the second quarter of 2011, Vertex Pharma reported total revenue of $659.2 million, almost double the Zacks Consensus Estimate of $342 million and significantly above the year-ago figure of $23.8 million. Vertex Pharma’s third quarter revenues consisted of revenue earned from the sale of Incivek ($419.6 million), royalty revenue (up 4.5% to $8.5 million) and collaborative revenue (up 137.9% to $231.1 million). Collaborative revenue for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/02/vrtx-vertex-pharmaceuticals-riding-high-on-incivek-sales/86343/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRTX) Vertex Pharmaceuticals Reports Positive Data</title>
		<link>http://www.stockbloghub.com/2011/09/12/vrtx-vertex-pharmaceuticals-reports-positive-data/82979</link>
		<comments>http://www.stockbloghub.com/2011/09/12/vrtx-vertex-pharmaceuticals-reports-positive-data/82979#comments</comments>
		<pubDate>Mon, 12 Sep 2011 17:19:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BID]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[RA]]></category>
		<category><![CDATA[Railamerica Inc]]></category>
		<category><![CDATA[Sotheby's]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82979</guid>
		<description><![CDATA[Vertex Pharmaceuticals Inc. (VRTX) reported positive data from a mid-stage trial on VX-509, which is being studied for the treatment of moderate to severe rheumatoid arthritis (RA). The 12-week study, which evaluated four doses of the candidate, met both the primary endpoints. Data from the two highest dose (100 mg and 150 mg) treatment arms demonstrated significant improvement in the proportion of people who achieved at least a 20% improvement in the signs and symptoms of RA (ACR20), and a statistically significant improvement from baseline in Disease Activity Score 28 (DAS28), compared to placebo. The study also met the secondary endpoints (ACR50 and ACR70) of achieving statistically significant responses compared to placebo. On the basis of the data from the phase IIa study, Vertex Pharma plans to initiate a six-month ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/12/vrtx-vertex-pharmaceuticals-reports-positive-data/82979/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VVUS) Vivus&#8217; Loss Narrowed Due To Lower Spend</title>
		<link>http://www.stockbloghub.com/2011/08/09/vvus-vivus-loss-narrowed-due-to-lower-spend/80947</link>
		<comments>http://www.stockbloghub.com/2011/08/09/vvus-vivus-loss-narrowed-due-to-lower-spend/80947#comments</comments>
		<pubDate>Tue, 09 Aug 2011 19:24:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Consolidated Edison Inc.]]></category>
		<category><![CDATA[ED]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[OC]]></category>
		<category><![CDATA[Owens Corning]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80947</guid>
		<description><![CDATA[Vivus Inc. (VVUS) posted adjusted loss of 14 cents per share during the second quarter of fiscal 2011, in line with the Zacks Consensus Estimate. However, the loss was narrower than the year-ago loss of 27 cents per share. Lower operating expenses led to the narrower loss. The company did not record any revenues during the quarter, similar to the prior-year quarter. The Zacks Consensus Estimate for the quarter was $1 million. Quarterly Details During the quarter, research and development (R&#38;D) expenses decreased 18.7% to $11.0 million. Moreover, general and administrative expenses amounted to $5.3 million, reflecting a decline of 21.4%. Vivus experienced reduced R&#38;D spends during the reported quarter, as both Qnexa and avanafil have completed their clinical studies and have been filed for regulatory approval. Pipeline Update In ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/09/vvus-vivus-loss-narrowed-due-to-lower-spend/80947/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRTX) Vertex Pharmaceuticals Loss Reduced by Incivek</title>
		<link>http://www.stockbloghub.com/2011/08/01/vrtx-vertex-pharmaceuticals-loss-reduced-by-incivek/80310</link>
		<comments>http://www.stockbloghub.com/2011/08/01/vrtx-vertex-pharmaceuticals-loss-reduced-by-incivek/80310#comments</comments>
		<pubDate>Mon, 01 Aug 2011 16:40:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CF]]></category>
		<category><![CDATA[CF Industries Holdings Inc.]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80310</guid>
		<description><![CDATA[Vertex Pharmaceuticals Inc. (VRTX) posted second quarter 2011 loss (including stock-based compensation expense) of 82 cents per share, narrower than the Zacks Consensus Estimate of 93 cents and the year-ago loss of 83 cents. Increased revenues from the sale of hepatitis C virus (HCV) candidate, Incivek (telaprevir) helped reduce the loss. Revenues Riding on the strong sales of Incivek, which was launched during the quarter, total revenue soared 262% to $114.4 million, surpassing the Zacks Consensus Estimate of $54 million. Vertex Pharma’s first quarter revenues consisted of revenue earned from the sale of Incivek ($74.5 million), royalty revenue (up 37.8% to $10.0 million) and collaborative revenue (up 22.7% to $30.0 million). The company receives royalty from GlaxoSmithKline plc (GSK) on sales of Lexiva, a HIV protease inhibitor. Collaborative revenue consists ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/01/vrtx-vertex-pharmaceuticals-loss-reduced-by-incivek/80310/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MAA) Mid-America Apartment Communities Buys Assets in Florida</title>
		<link>http://www.stockbloghub.com/2011/06/29/maa-mid-america-apartment-communities-buys-assets-in-florida/77576</link>
		<comments>http://www.stockbloghub.com/2011/06/29/maa-mid-america-apartment-communities-buys-assets-in-florida/77576#comments</comments>
		<pubDate>Wed, 29 Jun 2011 17:08:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[REIT - Residential]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[UDR]]></category>
		<category><![CDATA[UDR Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77576</guid>
		<description><![CDATA[Mid-America Apartment Communities Inc. (MAA) recently completed the acquisition of a 279-unit luxury apartment community Tattersall at Tapestry Park, located in the Southeast sub-market of Jacksonville, Florida. The acquisition was funded by a combination of share offerings and borrowings under the company’s current credit facilities. Developed in 2009 as the second phase of a mixed-use development project, Tattersall at Tapestry Park is a condo-quality community. The apartment community possesses numerous residential facilities including a four-story parking garage, lush landscapes with relaxing water features and a sundeck pool. MAA, however, did not buy the first phase of the development, which included condominiums, retail and office space, restaurants and a hotel. The acquisition will likely be accretive for Mid-America given Jacksonville has the largest deepwater port in the south and is the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/maa-mid-america-apartment-communities-buys-assets-in-florida/77576/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Company Presents Data on Two Studies</title>
		<link>http://www.stockbloghub.com/2011/06/29/bmy-bristol-myers-squibb-company-presents-data-on-two-studies/77782</link>
		<comments>http://www.stockbloghub.com/2011/06/29/bmy-bristol-myers-squibb-company-presents-data-on-two-studies/77782#comments</comments>
		<pubDate>Wed, 29 Jun 2011 16:34:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77782</guid>
		<description><![CDATA[Recently, Bristol-Myers Squibb Company (BMY) and partner AstraZeneca (AZN) presented encouraging data from two late-stage studies which evaluated their type II diabetes candidate dapagliflozin in conjunction with the extended-release version of metformin (XR). Data from the two 24-week studies, which evaluated adults suffering from type II diabetes, were presented at the American Diabetes Association (ADA) Scientific Sessions. Data from the studies revealed that there was a significant reduction in blood sugar levels in patients treated with dapagliflozin and metformin XR versus those treated with dapagliflozin or metformin XR alone and placebo. Moreover, no major events related to hypoglycemia were reported in the studies. Hypoglycemia refers to the situation of abnormally low levels of glucose in the blood. Results also revealed that patients treated with the combination of dapagliflozin and metformin ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/bmy-bristol-myers-squibb-company-presents-data-on-two-studies/77782/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TOL) U.S. Housing: Past and Future</title>
		<link>http://www.stockbloghub.com/2011/06/28/tol-u-s-housing-past-and-future/77727</link>
		<comments>http://www.stockbloghub.com/2011/06/28/tol-u-s-housing-past-and-future/77727#comments</comments>
		<pubDate>Tue, 28 Jun 2011 23:33:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Industrial Goods]]></category>
		<category><![CDATA[Residential Construction]]></category>
		<category><![CDATA[Avalonbay Communities Inc.]]></category>
		<category><![CDATA[AVB]]></category>
		<category><![CDATA[Beazer Homes USA Inc.]]></category>
		<category><![CDATA[BZH]]></category>
		<category><![CDATA[DHI]]></category>
		<category><![CDATA[DR Horton Inc.]]></category>
		<category><![CDATA[EQR]]></category>
		<category><![CDATA[Equity Residential]]></category>
		<category><![CDATA[HOV]]></category>
		<category><![CDATA[Hovnanian Enterprises Inc.]]></category>
		<category><![CDATA[KB Home]]></category>
		<category><![CDATA[KBH]]></category>
		<category><![CDATA[LEN]]></category>
		<category><![CDATA[Lennar Corporation]]></category>
		<category><![CDATA[M-I Homes Inc]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[MHO]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[PHM]]></category>
		<category><![CDATA[Pulte Homes Inc.]]></category>
		<category><![CDATA[RYL]]></category>
		<category><![CDATA[Ryland Group Inc.]]></category>
		<category><![CDATA[SPF]]></category>
		<category><![CDATA[Standard Pacific Corporation]]></category>
		<category><![CDATA[TOL]]></category>
		<category><![CDATA[Toll Brothers Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77727</guid>
		<description><![CDATA[I recently came across this piece written by Larry Kudlow, the host of two shows on CNBC. It is from June 20, 2005: “Homebuilders led the stock parade this week with a fantastic 11 percent gain. This is a group that hedge funds and bubbleheads love to hate. All the bond bears have been dead wrong in predicting sky-high mortgage rates. So have all the bubbleheads who expect housing-price crashes in Las Vegas or Naples, Florida, to bring down the consumer, the rest of the economy, and the entire stock market. None of this has happened&#8230;[T]he homebuilders index has increased 76 percent over the past year, with particularly well-run companies like Toll Brothers (TOL) up about twice as much. The bubbleheads missed all this because they haven’t done their homework&#8230;. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/28/tol-u-s-housing-past-and-future/77727/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Analyst Mintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/06/24/ctic-cell-therapeutics-analyst-mintains-neutral-on-shares/77315</link>
		<comments>http://www.stockbloghub.com/2011/06/24/ctic-cell-therapeutics-analyst-mintains-neutral-on-shares/77315#comments</comments>
		<pubDate>Fri, 24 Jun 2011 16:03:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CTIC]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[MDS]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[Midas Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77315</guid>
		<description><![CDATA[We are maintaining a Neutral recommendation on Cell Therapeutics Inc. (CTIC) with a target price of $2.25. Cell Therapeutics Inc. based in Seattle, Washington, is focused on developing drugs for cancer. The company’s lead pipeline candidate, pixantrone, is being developed for the treatment of hematologic malignancies and solid tumors. In December 2010, Cell Therapeutics filed an appeal against the decision of the FDA in April 2010 to deny approval to pixantrone for the treatment of relapsed, aggressive non-Hodgkin&#8217;s lymphoma, or NHL, in patients who have not responded to other treatment options. The approval was denied due to concerns that the late stage trial PIX301 (which formed the basis of the NDA filing) had not sufficiently proved the effectiveness of the drug. The FDA asked Cell Therapeutics to conduct an additional ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/24/ctic-cell-therapeutics-analyst-mintains-neutral-on-shares/77315/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MAA) Roche Holdings&#8217; Skin Cancer Drug Impresses</title>
		<link>http://www.stockbloghub.com/2011/06/12/maa-roche-holdings-skin-cancer-drug-impresses/75908</link>
		<comments>http://www.stockbloghub.com/2011/06/12/maa-roche-holdings-skin-cancer-drug-impresses/75908#comments</comments>
		<pubDate>Sun, 12 Jun 2011 17:14:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[REIT - Residential]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=75908</guid>
		<description><![CDATA[Roche Holdings Ltd. (RHHBY) recently presented encouraging data from a phase III trial (BRIM 3) on BRAF V600 mutation-positive metastatic melanoma candidate, vemurafenib (RG7204, PLX4032), at the annual meeting of the American Society of Clinical Oncology (ASCO). The BRIM 3 study was conducted to compare vemurafenib with dacarbazine (chemotherapy) in patients with previously untreated BRAF V600 mutation-positive, unresected, locally advanced or metastatic melanoma (skin cancer). Upon comparison with chemotherapy, the study results demonstrated that patients on vemurafenib experienced a significant improvement in overall survival, with the risk of death reducing by 63%. The study also met the co-primary endpoint of reducing the risk of disease aggravation by 74% compared with chemotherapy. Last month, Roche submitted a new drug application (NDA) to the US Food and Drug Administration (FDA), for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/12/maa-roche-holdings-skin-cancer-drug-impresses/75908/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRTX) Vertex Pharmaceuticals Posts Wider Loss</title>
		<link>http://www.stockbloghub.com/2011/05/08/vrtx-vertex-pharmaceuticals-posts-wider-loss-2/73436</link>
		<comments>http://www.stockbloghub.com/2011/05/08/vrtx-vertex-pharmaceuticals-posts-wider-loss-2/73436#comments</comments>
		<pubDate>Sun, 08 May 2011 15:51:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73436</guid>
		<description><![CDATA[Vertex Pharmaceuticals Inc. (VRTX) posted first-quarter 2011 loss (including stock-based compensation expense) of $1.05 per share, in line with the Zacks Consensus Estimate, but wider than the year-ago loss of 80 cents. Increased expenses related to the potential launch of hepatitis C virus (HCV) candidate, Incivek (proposed US trade name for telaprevir), led to the higher loss. Revenues Revenues for the reported quarter increased 229% to $73.7 million, exceeding the Zacks Consensus Estimate of $25 million. First quarter revenues included a $50 million milestone payment received from Johnson &#38; Johnson (JNJ), on the acceptance of the Marketing Authorization Application (MAA) for Incivek in Europe. Vertex Pharma’s first quarter revenues consisted of royalty revenues (down 5.4% to $6.1 million) and collaborative revenues (up 321.9% to $67.6 million). The company receives royalty ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/08/vrtx-vertex-pharmaceuticals-posts-wider-loss-2/73436/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals Signs Manufacturing Deal</title>
		<link>http://www.stockbloghub.com/2010/05/25/optr-optimer-pharmaceuticals-signs-manufacturing-deal/38389</link>
		<comments>http://www.stockbloghub.com/2010/05/25/optr-optimer-pharmaceuticals-signs-manufacturing-deal/38389#comments</comments>
		<pubDate>Tue, 25 May 2010 22:15:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CDI]]></category>
		<category><![CDATA[CDI Corporation]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SLXP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=38389</guid>
		<description><![CDATA[Recently, Optimer Pharmaceuticals (OPTR) entered into a long-term supply agreement with India based Biocon Limited. The agreement is aimed at manufacturing the active pharmaceutical ingredient of fidaxomicin, Optimer’s lead candidate. Fidaxomicin is being developed to treat Clostridium difficile infection (CDI), the most common nosocomial or hospital-acquired, diarrhea. Following positive results from the second phase III trial of the drug in February 2010, Optimer is preparing to submit a new drug application in the second half of 2010. We believe the agreement with Biocon is a step towards the preparatory groundwork. While Optimer currently holds worldwide rights to fidaxomicin, it is on the lookout for a suitable partnership for the commercialization of fidaxomicin outside North America. Optimer also plans to submit a Marketing Authorization Application (MAA) for fidaxomicin with the European ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/25/optr-optimer-pharmaceuticals-signs-manufacturing-deal/38389/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MAA) Mid-America Apartment Communities Updates Earnings Guidance</title>
		<link>http://www.stockbloghub.com/2010/04/21/maa-mid-america-apartment-communities-updates-earnings-guidance/34552</link>
		<comments>http://www.stockbloghub.com/2010/04/21/maa-mid-america-apartment-communities-updates-earnings-guidance/34552#comments</comments>
		<pubDate>Wed, 21 Apr 2010 21:48:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[REIT - Residential]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34552</guid>
		<description><![CDATA[Mid-America Apartment Communities Inc. (MAA), an apartment-only real estate investment trust (REIT), has recently provided an updated first quarter 2010 earnings guidance based on strong occupancy and better-than-expected fee income. The company currently expects first quarter 2010 funds from operations (FFO) in the range of $30.1 million to $31.6 million or 96 cents to $1.00 per share. Fund from operations, a widely used metric to gauge the performance of REITs, is obtained after adding depreciation and amortization and other non-cash expenses to net income. The updated FFO figures exceed the earlier guidance of 86?96 cents per share. The earnings forecast also exceeds the current Zacks Consensus Estimate of 91 cents per share. Mid-America’s diversified market profile with its focus on solid employment markets of the Sunbelt region across both the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/21/maa-mid-america-apartment-communities-updates-earnings-guidance/34552/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AUXL) Auxilium Pharmaceuticals and Pfizer Announces EU Review Process</title>
		<link>http://www.stockbloghub.com/2010/01/25/auxl-auxilium-pharmaceuticals-and-pfizer-announces-eu-review-process/25897</link>
		<comments>http://www.stockbloghub.com/2010/01/25/auxl-auxilium-pharmaceuticals-and-pfizer-announces-eu-review-process/25897#comments</comments>
		<pubDate>Mon, 25 Jan 2010 20:28:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25897</guid>
		<description><![CDATA[Auxilium Pharmaceuticals, Inc. (AUXL) and Pfizer Inc. (PFE) recently announced that the review process of their Marketing Authorization Application (MAA) for Xiaflex has commenced in the European Union. Pfizer was informed by the European Medicines Agency (EMEA) that the Xiaflex MAA has completed the validation phase successfully resulting in the commencement of the review process on Jan 21, 2010. Auxilium is now eligible to receive a $15 million milestone payment from Pfizer based on the commencement of the review process. The development, commercialization and supply agreement with Pfizer for Xiaflex covers Europe and certain Eurasian countries. Going forward, Auxilium can earn an additional $135 million in regulatory milestones and $260 million in sales milestones, along with a tiered double-digit royalty on sales at Pfizer. Pfizer and Auxilium are currently seeking ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/25/auxl-auxilium-pharmaceuticals-and-pfizer-announces-eu-review-process/25897/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire Plc&#8217;s Drug Seeks European Medicines Agency Approval</title>
		<link>http://www.stockbloghub.com/2009/11/25/shpgy-shire-plcs-drug-seeks-european-medicines-agency-approval/21289</link>
		<comments>http://www.stockbloghub.com/2009/11/25/shpgy-shire-plcs-drug-seeks-european-medicines-agency-approval/21289#comments</comments>
		<pubDate>Wed, 25 Nov 2009 18:10:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21289</guid>
		<description><![CDATA[Shire plc (SHPGY) continues to make progress with its Gaucher disease candidate, velaglucerase alfa. The company recently submitted a marketing authorization application (MAA) to the European Medicines Agency (EMEA) for velaglucerase alfa for the treatment of type I Gaucher disease. The company has already asked for approval in other markets like the U.S. and Canada. Shire is seeking an accelerated review of the MAA. Given the shortage in supply of Genzyme’s (GENZ) Cerezyme, which is the leader in the treatment of patients with Gaucher disease, the Committee for Medicinal Products for Human Use (CHMP) has accepted Shire’s request. Accordingly, the review time has been reduced by 60 days to 150 days with the review scheduled to commence in December. Once approved and launched commercially, velaglucerase alfa will compete directly with ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/25/shpgy-shire-plcs-drug-seeks-european-medicines-agency-approval/21289/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca Beats Expectations and Raises</title>
		<link>http://www.stockbloghub.com/2009/11/14/azn-astrazeneca-beats-expectations-and-raises/20500</link>
		<comments>http://www.stockbloghub.com/2009/11/14/azn-astrazeneca-beats-expectations-and-raises/20500#comments</comments>
		<pubDate>Sat, 14 Nov 2009 22:31:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ADS]]></category>
		<category><![CDATA[Alliance Data Systems Corporation]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[Nektar Therapeutics]]></category>
		<category><![CDATA[NKTR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20500</guid>
		<description><![CDATA[AstraZeneca’s (AZN) third quarter earnings came in at $1.68 per American Depositary Shares (ADS), well above the Zacks Consensus Estimate of $1.36 and $1.32 reported in the year-ago period. Revenues increased 10% at constant exchange rates (CER) to $8.2 billion compared to the same period last year. The primary reasons for the increase in revenues were strong US sales of Toprol-XL benefiting from generic withdrawal, US sales of its H1N1 vaccine and robust growth in emerging markets. AstraZeneca recorded strong sales across all geographies. Sales in North America, Emerging Markets and Established Markets increased (at CER) by 13%, 15% and 4%, respectively. The company expects double-digit revenue growth in Emerging Markets for the full year. Among the product categories, apart from gastrointestinal and oncology, which recorded sales decline of 1% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/14/azn-astrazeneca-beats-expectations-and-raises/20500/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

